Metabolic Dysfunction–Associated Steatotic Liver Disease
The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucagon-like peptide-1 receptor agonist (GLP1RA) alone [129] or GLP1RA-based combination agents, including dual (e.g., tirzepatide and survodutide) and triple (e.g., retatrutide) agonists, now demonstrate histological improvements in MASH and fibrosis with weight loss approaching that of bariatric surgery [3,130-133].”
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
In the citing paper
“Importantly, resmetirom, a selective thyroid hormone receptor-β agonist, became the first U.S. Food and Drug Administration-approved drug for non-cirrhotic MASH with F2–F3 fibrosis.”
In the citing paper
“It has shown histologic improvement in MASH and liver fibrosis, as well as improvement of non-invasive biomarkers, with an acceptable safety profile [3,4].”
Citations
Cites
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Self-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00308-3 · Cited by 674
Self-citationValenti, L., Al‐Serri, A., Daly, A. K., Galmozzi, E., Rametta, R., Dongiovanni, P., Nobili, V., Mozzi, E., Roviaro, G., Vanni, E., et al. (2010) · Hepatology · doi:10.1002/hep.23622 · Cited by 651
Self-citationKanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607
Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586
Self-citationDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533
Self-citationLoomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut · doi:10.1136/gutjnl-2020-322572 · Cited by 481
Self-citationThiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine · doi:10.1038/s41591-023-02603-1 · Cited by 435
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut · doi:10.1136/gutjnl-2020-323082 · Cited by 402
Self-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385
Self-citationEn Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Global burden of metabolic diseases, 1990–2021
Zhang, H., Zhou, X.-D., Shapiro, M. D., Lip, G. Y. H., Tilg, H., Valenti, L., Somers, V. K., Byrne, C. D., Targher, G., Yang, W., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155999 · Cited by 368
Self-citationDongiovanni, P., Stender, S., Pietrelli, A., Mancina, R. M., Cespiati, A., Petta, S., Pelusi, S., Pingitore, P., Badiali, S., Maggioni, M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12719 · Cited by 367
Self-citationMantovani, A., Petracca, G., Beatrice, G., Csermely, A., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut · doi:10.1136/gutjnl-2021-324191 · Cited by 363
Self-citationYounossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.014 · Cited by 321
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
Self-citationHarrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00272-8 · Cited by 276
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMJ · doi:10.1136/bmj.l5367 · Cited by 254
PNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252
Self-citationMultiomics study of nonalcoholic fatty liver disease
Sveinbjornsson, G., Ulfarsson, M. O., Thorolfsdottir, R. B., Jonsson, B. A., Einarsson, E., Gunnlaugsson, G., Rognvaldsson, S., Arnar, D. O., Baldvinsson, M., Bjarnason, R. G., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01199-5 · Cited by 236
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
Chen, Y., Du, X., Kuppa, A., Feitosa, M. F., Bielak, L. F., O’Connell, J. R., Musani, S. K., Guo, X., Kahali, B., Chen, V. L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01497-6 · Cited by 215
Chen, V. L., Morgan, T. R., Rotman, Y., Patton, H. M., Cusi, K., Kanwal, F., & Kim, W. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001112 · Cited by 205
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
Cherubini, A., Torre, S. D., Pelusi, S., & Valenti, L. V. C. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.013 · Cited by 181
Self-citationHarrison, S. A., Browne, S. K., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Roberts, M. S., & Harris, M. S. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.006 · Cited by 176
Jamialahmadi, O., Vincentis, A. D., Tavaglione, F., Malvestiti, F., Li‐Gao, R., Mancina, R. M., Alvarez, M., Gelev, K. Z., Maurotti, S., Gentilucci, U. V., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03284-0 · Cited by 174
Self-citationNonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
Self-citationSanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024) · Liver International · doi:10.1111/liv.15930 · Cited by 171
Self-citationLin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., He, J., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 168
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Phoolchund, A. G. S., & Khakoo, S. I. (2024) · Cancers · doi:10.3390/cancers16020259 · Cited by 165
Noureddin, M., Charlton, M. R., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R., Sanyal, A. J., & Rinella, M. E. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.003 · Cited by 165
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Noureddin, M., Rinella, M. E., Chalasani, N., Neff, G. W., Lucas, K. J., Rodriguez, M. E., Rudraraju, M., Patil, R., Behling, C. A., Burch, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502242 · Cited by 163
Kanwal, F., Kramer, J. R., Li, L., Yang, Y.-X., Cao, Y., Yu, X., Samuel, R., Ali, B., Desiderio, R., Cholankeril, G., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4661 · Cited by 156
Hepatic lipid droplet biology: Getting to the root of fatty liver
Mashek, D. G., Khan, S. A., Sathyanarayan, A., Ploeger, J. M., & Franklin, M. P. (2015) · Hepatology · doi:10.1002/hep.27839 · Cited by 148
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 134
Self-citationWang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 130
Thomas, J. A., Kendall, B. J., Dalais, C., Macdonald, G. A., & Thrift, A. P. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.051 · Cited by 129
Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease
Pelusi, S., Baselli, G., Pietrelli, A., Dongiovanni, P., Donati, B., McCain, M. V., Meroni, M., Fracanzani, A. L., Romagnoli, R., Petta, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39998-2 · Cited by 125
Self-citationZeng, X.-F., Varady, K. A., Wang, X.-D., Targher, G., Byrne, C. D., Tayyem, R., Latella, G., Bergheim, I., Valenzuela, R., George, J., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156028 · Cited by 124
Self-citationAbdelmalek, M. F., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Lawitz, E. J., Harrison, S. A., Jacobson, I. M., Imajo, K., Gunn, N., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.012 · Cited by 110
Le, P. N. B., Payne, J. Y., Zhang, L., Deshpande, A., Rothberg, M. B., Alkhouri, N., Herman, W. H., Hernández, A. V., Schleicher, M. C., Ye, W., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.07.033 · Cited by 102
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 93
Self-citationGhouse, J., Sveinbjörnsson, G., Vujković, M., Seidelin, A.-S., Gellert‐Kristensen, H., Ahlberg, G., Tragante, V., Rand, S. A., Brancale, J., Vilarinho, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01720-y · Cited by 92
Wester, A., Shang, Y., Grip, E. T., Matthews, A., & Hagström, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330962 · Cited by 91
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Self-citationSelective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
Cusi, K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2314365 · Cited by 78
Lin, R., Sun, Q., Xin, X., Ng, C. H., Valenti, L. V. C., Hu, Y., Zheng, M., & Feng, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156043 · Cited by 73
Self-citationBea, S., Ko, H. Y., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2024) · Gut · doi:10.1136/gutjnl-2024-332687 · Cited by 68
Self-citationMetabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes
Shang, Y., Grip, E. T., Modica, A., Skröder, H., Ström, O., Ntanios, F., Gudbjörnsdottir, S., & Hagström, H. (2024) · Diabetes Care · doi:10.2337/dc23-1937 · Cited by 61
Mantovani, A., Csermely, A., Bilson, J., Borella, N., Enrico, S., Pecoraro, B., Shtembari, E., Morandin, R., Pοlyzos, S. A., Valenti, L. V. C., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332491 · Cited by 57
Self-citationShankar, S. S., Daniels, S. J., Robertson, D., Sarv, J., Sánchez, J., Carter, D., Jermutus, L., Challis, B., & Sanyal, A. J. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.04.017 · Cited by 56
The contribution of genetics and epigenetics to MAFLD susceptibility
Moretti, V., Romeo, S., & Valenti, L. V. C. (2024) · Hepatology International · doi:10.1007/s12072-024-10667-5 · Cited by 53
Self-citationGenetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Bianco, C., Casirati, E., Malvestiti, F., & Valenti, L. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100284 · Cited by 50
Self-citationTargher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2025) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 48
Self-citationMantovani, A., Morandin, R., Sani, E., Fiorio, V., Shtembari, E., Bonapace, S., Petta, S., Pοlyzos, S. A., Byrne, C. D., & Targher, G. (2024) · Liver International · doi:10.1111/liv.16218 · Cited by 44
Self-citationDistinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
Valenti, L. V. C., Pedica, F., & Colombo, M. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.023 · Cited by 35
Self-citationMantovani, A., Morandin, R., Lando, M. G., Fiorio, V., Pennisi, G., Petta, S., Stefan, N., Tilg, H., Byrne, C. D., & Targher, G. (2025) · Diabetes Care · doi:10.2337/dc25-0282 · Cited by 26
Self-citationMantovani, A., Tilg, H., & Targher, G. (2023) · Gut · doi:10.1136/gutjnl-2023-331115 · Cited by 20
Self-citationCombination Treatment in MASLD: The Next Frontier
Tsochatzis, E. A., & Noureddin, M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.021 · Cited by 7
Research works printed but not linked: 1
- 10.1136/gutjnl-2020-323082 · DOI · Paper page
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkuş, E., Koudelková, K., Cerini, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70132 · Cited by 40
Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 36
Self-citationHuman genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
Mancina, R. M., Valenti, L. V. C., & Romeo, S. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01394-8 · Cited by 32
Self-citationZhou, X., Fan, Q.-Y., Targher, G., Byrne, C. D., Chen, Q., Shapiro, M. D., Dong, Y.-X., Sung, K., Lip, G. Y. H., Lazarus, J. V., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3193-9 · Cited by 27
Self-citation
Metadata
- Authors
- Targher, G., Valenti, L., & Byrne, C. D.
- Affiliations
- University of Verona (IT)
- University of Milan (IT)
- University Hospital Southampton NHS Foundation Trust (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-08-14
- Volume
- 393
- Issue
- 7
- Pages
- 683-698
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4413117974
- Cited by
- 325
- References
- 82
- Citations by year
- 2026: 285 · 2025: 40
- FWCI
- 49.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, metabolic dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.